Lessons from immuno-oncology: a new era for cancer nanomedicine?
Nature Reviews Drug Discovery 16, 369 (2017).
doi:10.1038/nrd.2017.34
Authors: Wen Jiang, Hengfeng Yuan, Charles K. Chan, Christina A. von Roemeling, Zuoqin Yan, Irving L. Weissman & Betty Y. S. Kim
Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with immuno-oncology therapies could be applied to cancer nanomedicine and how this may help to overcome some (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - March 17, 2017 Category: Drugs & Pharmacology Authors: Wen Jiang Hengfeng Yuan Charles K. Chan Christina A. von Roemeling Zuoqin Yan Irving L. Weissman Betty Y. S. Kim Tags: Comment Source Type: research
Strategies and challenges for the next generation of antibody – drug conjugates
Nature Reviews Drug Discovery 16, 315 (2017).
doi:10.1038/nrd.2016.268
Authors: Alain Beck, Liliane Goetsch, Charles Dumontet & Nathalie Corvaïa
Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clinical trials that are evaluating more than 60 (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - March 17, 2017 Category: Drugs & Pharmacology Authors: Alain Beck Liliane Goetsch Charles Dumontet Nathalie Corva ï a Tags: Review Source Type: research
Strategies and challenges for the next generation of antibody –drug conjugates
Nature Reviews Drug Discovery 16, 315 (2017).
doi:10.1038/nrd.2016.268
Authors: Alain Beck, Liliane Goetsch, Charles Dumontet & Nathalie Corvaïa
Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clinical trials that are evaluating more than 60 (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - March 17, 2017 Category: Drugs & Pharmacology Authors: Alain Beck Liliane Goetsch Charles Dumontet Nathalie Corva ïa Tags: Review Source Type: research
To cleave or not to cleave: therapeutic gene editing with and without programmable nucleases
Nature Reviews Drug Discovery 16, 296 (2017).
doi:10.1038/nrd.2017.42
Authors: Tod M. Woolf, Channabasavaiah B. Gurumurthy, Frederick Boyce & Eric B. Kmiec
In recent years, pioneering clinical studies involving the use of programmable nucleases to achieve gene editing have begun to evaluate the therapeutic potential of such approaches. For example, Sangamo BioSciences has reported successful proof-of-concept clinical studies to treat HIV infection using an engineered zinc-finger nuclease (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - March 17, 2017 Category: Drugs & Pharmacology Authors: Tod M. Woolf Channabasavaiah B. Gurumurthy Frederick Boyce Eric B. Kmiec Tags: Correspondence Source Type: research
Market watch: Upcoming market catalysts in Q2 2017
Nature Reviews Drug Discovery 16, 231 (2017).
doi:10.1038/nrd.2017.47
Author: Eric Ho
Important market catalysts expected in the second quarter of 2017 include regulatory decisions by the FDA on cerliponase alfa (developed by BioMarin) for treatment of CLN2 disease and brigatinib (developed by Takeda) for the treatment of non-small-cell lung cancer (NSCLC), as well as top-line phase (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - March 17, 2017 Category: Drugs & Pharmacology Authors: Eric Ho Tags: News and Analysis Source Type: research
